Ly-294002

Ly-294002

SCHEMBL94377

O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 18/20 1.00
ALDH1A1 P00352 3/20 1.00
KDM4E B2RXH2 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
BRD4 O60885 2/20 1.00
BRD2 P25440 2/20 1.00
BRD3 Q15059 2/20 1.00
PIK3CD O00329 1/20 1.00
PDE2A O00408 1/20 1.00
PIK3C2A O00443 1/20 1.00
PIK3R2 O00459 1/20 1.00
PIK3C2B O00750 1/20 1.00
PDE5A O76074 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
PIM1 P11309 1/20 1.00
CYP2C9 P11712 1/20 1.00
ALOX15 P16050 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ly-294002 SCHEMBL29424167 1.00 PRKDC (1.00) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
Ly-294002 SCHEMBL5078472 0.99 ALDH1A1 (1.00) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL13496867 0.99 PRKDC (0.97) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL31061056 0.95 PRKDC (1.00) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL14041172 0.94 PRKDC (1.00) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL5261685 0.90 PRKDC (0.81) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL5260468 0.90 PRKDC (0.81) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL4423159 0.90 PRKDC (0.81) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL31060584 0.89 PRKDC (1.00) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4
SCHEMBL13700043 0.89 PRKDC (0.80) PRKDCALDH1A1KDM4ESMN1; SMN2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2273 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122038285-A Kit and method for constructing human bone organ by using pluripotent stem cells 广东医科大学附属医院 2026-05-15 CN claimed
US-20260053761-A1 USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2026-02-26 US claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 US claimed
EP-4333822-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION Lead Discovery Center GmbH (DE) 2024-03-13 EP claimed
US-11898155-B2 Method for introducing molecule and composition containing inhibitor PEARL KOGYO CO., LTD. (JP) 2024-02-13 US claimed
WO-2024026458-A2 USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER THE UNIVERSITY OF VERMONT (US) 2024-02-01 WO claimed
EP-3468559-B1 METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS DANA FARBER CANCER INST INC (US) 2023-11-22 EP claimed
US-20230323299-A1 POPULATION OF TREG CELLS FUNCTIONALLY COMMITTED TO EXERT A REGULATORY ACTIVITY AND THEIR USE FOR ADOPTIVE THERAPY INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-10-12 US claimed
US-20230310452-A1 BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS MDI BIOLOGICAL LABORATORY (US) 2023-10-05 US claimed
US-20230255974-A1 USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE 2023-08-17 US claimed
EP-1543119-A2 METHODS OF INHIBITING HIV-1 VPR ACTIVITY AND HIV-1 INFECTIVITY USING ATR OR RAD17 INHIBITORS UNIVERSITY OF ROCHESTER (US) 2005-06-22 EP claimed
WO-2004090106-A2 CRYSTAL STRUCTURES OF HUMAN PIM-1 KINASE PROTEIN COMPLEXES AND BINDING POCKETS THEREOF, AND USES THEREOF IN DRUG DESIGN VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-10-21 WO claimed
EP-1442132-A2 METHODS FOR THE TREATMENT OF OSTEOARTHRITIS AND COMPOSITIONS THEREOF Novartis AG (CH) 2004-08-04 EP claimed
EP-1196153-B1 PROCESS FOR THE IMPROVEMENT OF SPERMATOZOA FERTILIZATION ACTIVITY APPLIED RESEARCH SYSTEMS (AN) 2003-11-19 EP claimed
WO-2003068929-A9 METHODS OF INHIBITING HIV-1 VPR ACTIVITY AND HIV-1 INFECTIVITY USING ATR OR RAD17 INHIBITORS UNIV ROCHESTER (US) 2003-10-23 WO claimed
WO-2003068929-A2 METHODS OF INHIBITING HIV-1 VPR ACTIVITY AND HIV-1 INFECTIVITY USING ATR OR RAD17 INHIBITORS UNIVERSITY OF ROCHESTER (US) 2003-08-21 WO claimed
WO-2003035048-A2 METHODS FOR THE TREATMENT OF OSTEOARTHRITIS AND COMPOSITIONS THEREOF NOVARTIS AG (CH) 2003-05-01 WO claimed
JP-2003505412-A 2003-02-12 JP claimed
EP-1196153-A2 PROCESS FOR THE IMPROVEMENT OF SPERMATOZOA FERTILIZATION ACTIVITY Applied Research Systems ARS Holding N.V. (AN) 2002-04-17 EP claimed
WO-2001007021-A2 PROCESS FOR THE IMPROVEMENT OF SPERMATOZOA FERTILIZATION ACTIVITY APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-02-01 WO claimed